In a study published in the Journal of Molecular Cancer Research, researchers identified the protein as a potential therapeutic target for high-grade serous ovarian cancer cells.
] List of Non-Spreading Ovarian Carcinoma Cell Lines: Recent research suggests that prevention of the development and division of a particular type of ovarian carcinoma cell line may interfere with the action of a protein. According to a recent study published in the Journal of Molecular Cancer Research, scientists have identified the protein as the major therapeutic target for high-grade serous ovarian cancer cells. Almost seventy percent of sufferers of this type of ovarian cancer suffer from a chemoresistant disease. However, it increases the demand for new treatment solutions.
Katherine Aird, the researcher's other researcher, has discovered a promising technique to "sleep" high grade serous ovarian cancer cells. This condition is also called senescence. According to Aird, one of the biggest problems with these cancer cells is that they can develop forever without any stimulus. However, by promoting sleep, cells can no longer develop and divide.
Read also: Signs of Pregnancy in Breastfeeding Mothers
Ovarian cancer cells degrade the existing chemicals and are needed for the maintenance of life. These cells support different pathways and cycles in a process called metabolism.
Erika Dahl, the lead author of the paper, said that it is a symbol of cancer cells, that their metabolic processes are generally differentiated from normal to healthy cells. Using spectrometry, the metabolites in each cell line were measured. However, after comparing the differences in their metabolic processes, the laboratory noted that
Read also: PM Modi, Akshay Kumar and Virat Kohli ranked in the list of health effects of GOQii 2019
- Ovarian cancer cells prefer the use of sugar in the citric acid cycle.
- Ovarian cancer cells do not produce lactate. However, it is the more usual way.
Dahl added that several therapies may target glycolysis, but this is not the best resolution. She found that targeted glycolysis sometimes entails the risk of toxic damage to normal to healthy tissue.
According to Katherine Aird, the Food and Drug Administration has already certified a medicine that labels the mutated form of the protein. One of the drugs that marks the mutated form may also recognize the wild-type form. However, one of their sustainable goals is to test and re-use this already certified medicine as a diagnosis of this type of ovarian cancer.
Other articles on Health News
Submitted by: Tavishi Dogra
Source: Editorial staff of Onlymyhealth July 15, 2019